Tenet Healthcare Corporation $THC Shares Sold by Horizon Investments LLC

Key Points

• Horizon Investments reduced its stake in Tenet Healthcare by 23.6% in Q4, selling 9,279 shares and retaining 30,052 shares valued at about $5.97 million.
• Insider selling has been notable recently — R. Scott Ramsey sold 8,017 shares (~$1.87M) and EVP Paola M. Arbour sold 6,500 shares (~$1.55M), with insiders offloading a total of 46,517 shares (~$10.94M) over the past 90 days (insiders own ~0.81%).
• Tenet beat Q1 EPS estimates ($4.82 vs. $4.21) while revenue was roughly in line at $5.37B, is pursuing outpatient growth via ASC acquisitions (~$125M deployed in Q1), and issued FY2026 EPS guidance of 16.38–18.68 amid a consensus analyst EPS forecast of ~17.42 and a "Moderate Buy" consensus rating.

Horizon Investments LLC reduced its stake in Tenet Healthcare Corporation (NYSE:THC - Free Report) by 23.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,052 shares of the company's stock after selling 9,279 shares during the period. Horizon Investments LLC's holdings in Tenet Healthcare were worth $5,972,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of THC. Triumph Capital Management purchased a new position in Tenet Healthcare in the third quarter valued at $25,000. Activest Wealth Management purchased a new position in Tenet Healthcare in the fourth quarter valued at $26,000. William B. Walkup & Associates Inc. purchased a new position in Tenet Healthcare in the third quarter valued at $32,000. Canada Pension Plan Investment Board purchased a new position in Tenet Healthcare in the second quarter valued at $35,000. Finally, Westside Investment Management Inc. increased its holdings in Tenet Healthcare by 100.0% in the third quarter. Westside Investment Management Inc. now owns 192 shares of the company's stock valued at $39,000 after buying an additional 96 shares during the last quarter. Hedge funds and other institutional investors own 95.44% of the company's stock.

Insider Buying and Selling at Tenet Healthcare

In other Tenet Healthcare news, insider R. Scott Ramsey sold 8,017 shares of Tenet Healthcare stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $232.70, for a total value of $1,865,555.90. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Paola M. Arbour sold 6,500 shares of Tenet Healthcare stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $238.43, for a total value of $1,549,795.00. Following the completion of the sale, the executive vice president directly owned 29,291 shares in the company, valued at $6,983,853.13. This represents a 18.16% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 46,517 shares of company stock valued at $10,943,111. 0.81% of the stock is owned by corporate insiders.

Tenet Healthcare News Roundup

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: Q1 earnings beat and solid profitability — Tenet reported $4.82 EPS, well ahead of consensus, and showed healthy margins and ROE; investors favor the earnings beat even though revenue was roughly in-line. Tenet Healthcare (THC) Q1 Earnings Top Estimates
• Positive Sentiment: Strategic growth via ASC acquisitions — Tenet deployed ~$125M to acquire seven ambulatory surgery centers in Q1 and signals more M&A in the outpatient space, supporting revenue diversification and higher-margin outpatient growth. Tenet deployed $125M on 7 ASC acquisitions in Q1, eyes more deals
• Positive Sentiment: Operational momentum in procedures and robotics — The company is seeing double‑digit joint replacement growth and expanding robotic programs across ASCs/hospitals, evidence that its outpatient acuity push is producing revenue mix benefits longer term. Double-digit joint replacement growth
• Neutral Sentiment: Analysts trimmed price targets but kept Buy/Outperform/Overweight ratings — Multiple firms cut PTs (RBC to $236, Guggenheim to $252, Wells Fargo to $213, KeyCorp to $225) while retaining positive ratings, which gives the stock continued sell‑side endorsement but signals more conservative valuation assumptions. Analyst price target coverage (Benzinga summaries) TickerReport coverage
• Neutral Sentiment: Market commentary and investor takeaways — Several pieces are advising investors to weigh analyst views and the company’s outpatient strategy at current levels; these articles are shaping investor positioning rather than delivering new fundamental news. Seeking Alpha: Investor commentary
• Negative Sentiment: Revenue softness and admissions‑mix headwinds — Management flagged admissions mix and external disruptions as reasons revenue missed expectations modestly; that weak revenue signal tempers the EPS beat and is the main near-term risk. Tenet Healthcare Blames Admissions Mix For Soft Q1 Sales

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. UBS Group increased their target price on Tenet Healthcare from $260.00 to $288.00 and gave the company a "buy" rating in a report on Thursday, February 12th. Leerink Partners raised their price objective on Tenet Healthcare from $255.00 to $264.00 and gave the stock an "outperform" rating in a report on Friday, February 20th. Guggenheim dropped their price objective on Tenet Healthcare from $283.00 to $252.00 and set a "buy" rating on the stock in a report on Friday. Wall Street Zen raised Tenet Healthcare from a "buy" rating to a "strong-buy" rating in a report on Sunday. Finally, TD Cowen reaffirmed a "buy" rating on shares of Tenet Healthcare in a report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, Tenet Healthcare has a consensus rating of "Moderate Buy" and a consensus price target of $241.94.

Tenet Healthcare Stock Performance

NYSE THC opened at $183.23 on Monday. The company has a quick ratio of 1.30, a current ratio of 1.36 and a debt-to-equity ratio of 1.96. Tenet Healthcare Corporation has a 52-week low of $145.27 and a 52-week high of $247.21. The business's 50-day moving average price is $207.31 and its 200 day moving average price is $204.33. The firm has a market cap of $16.05 billion, a P/E ratio of 9.53, a P/E/G ratio of 1.37 and a beta of 1.30.

Tenet Healthcare (NYSE:THC - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported $4.82 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.21 by $0.61. Tenet Healthcare had a return on equity of 25.55% and a net margin of 7.94%.The firm had revenue of $5.37 billion for the quarter, compared to analyst estimates of $5.39 billion. During the same quarter last year, the company posted $4.36 earnings per share. The business's revenue was up 2.6% on a year-over-year basis. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. On average, equities research analysts expect that Tenet Healthcare Corporation will post 17.42 earnings per share for the current year.

Tenet Healthcare Profile

Tenet Healthcare Corporation NYSE: THC is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet's operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.